IMMB Stock UPDATES Immunotech Laborator (IMMB) 0.0064 10/23/2014
Post# of 273217
Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease (“EVD”) Treatment and Implement Strategy for Company's ITV-1 Infectious Diseases Treatment in Africa
Filing Services Canada XHTML - Tue Oct 21, 7:03AM CDT
Immunotech Laboratories, Inc. Enters into Agreement to Market Potential Ebola Virus Disease ("EVD" Treatment and Implement Strategy for Company's ITV-1 Infectious Diseases Treatment in Africa
Business Wire - Tue Oct 21, 7:00AM CDT
Immunotech Laboratories, Inc. (OTC PINK: IMMB) ("Immunotech" or the "Company" and wholly-owned subsidiary Immunotech Laboratories, BG (IMMB-BG) today announced that they have successfully completed negotiations with Uldic Investment Pvt. Ltd. (Uldic), located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus, and to conduct human clinical trials using the Company's HIV/AIDS and Hepatitis C virus treatment, Immune Therapeutic Vaccine-1 (ITV-1), in Sub-Saharan West Africa.
Immunotech Laboratories, Inc. Enters into Negotiations with Uldic Investment Pvt. Ltd. for Market Development
Filing Services Canada XHTML - Thu Oct 09, 7:45AM CDT
Immunotech Laboratories, Inc. Enters Into Negotiations With Uldic Investment Pvt. Ltd. For Market Development
Business Wire - Thu Oct 09, 7:45AM CDT
Immunotech Laboratories, Inc. (OTCMARKETS: IMMB) Immunotech Laboratories, Inc.(the "Company" and Immunotech Laboratories, BG (IMMB-BG" the Company announced today that they have entered into negotiations with Uldic Investment Pvt. Ltd. ("Uldic" or the "Representative/Distributor" , located in Zimbabwe, to pursue the development of market opportunities and Clinical Testing for the Company's HIV/AIDS and Hepatitis C virus treatment ("ITV-1 Treatment" in Africa, initially focusing on clinical testing for Hepatitis C in Mauritius Island and Malawi.
Immunotech Laboratories, Inc. Updates Progress on Negotiations for Phase III Testing on its Treatments for HIV/AIDS and Hepatitis C Viruses in Macedonia and Serbia
Filing Services Canada XHTML - Tue Oct 07, 8:03AM CDT
Immunotech Laboratories, Inc. Announces Successful Completion of Phase I and Phase II Field Trials of the Company's Patented Treatment of the HIV/AIDS and Hepatitis C Viruses
Business Wire - Thu Aug 28, 8:00AM CDT
Immunotech Laboratories, Inc. (OTCMARKETS:IMMB) Immunotech Laboratories, Inc. announced today that the Phase I and Phase II field trials in Bulgaria of the Company's HIV/AIDS and Hepatitis C virus treatment ("ITV-1 Treatment" have been successfully completed. The clinical test are being conducted through Immunotech Laboratories, BG ("IMMB-BG" a 49% owned subsidiary of Immunotech Laboratories. Since 2013, IMMB-BG hired and funded the Clinical Research Organization ("CRO" to conduct all preclinical and monitoring Phase III clinical studies. The product for the Bulgarian study was produced under GMP conditions by a U.S. Contract Manufacturing Facility.
Agile Therapeutics Announces Appointment of Science Advisory Board Member
PR Newswire - Thu Feb 13, 7:30AM CST
Agile Therapeutics, a specialty pharmaceutical company focused on women's health, announced today that Daniel A. Shames M.D., F.A.C.S., has joined its Scientific Advisory Board. Dr. Shames is an experienced clinician with extensive experience in pharmaceutical development and regulatory affairs. His experience includes over ten years of practice at the U.S. Food and Drug Administration (FDA) where he served as Deputy Director, Office of Drug Evaluation III/Center for Drug Evaluation and Research (CDER) from 2006 to 2008, as well as a member of the Senior Management Team of the Office of New Drugs and the Drug Safety Oversight Board. Since 2008, as President of Daniel A. Shames Consulting, Inc., he has been an independent clinical/regulatory consultant on a wide range of pharmaceutical issues. Dr. Shames began his career with the FDA in 1996 and held positions as Primary Medical Officer, Team Leader and Deputy Director in the Division of Reproductive and Urologic Products (DRUP). From 2001 to 2006, he served as Director of DRUP and reviewed therapeutic products for clinical areas including contraception, infertility, obstetrics, menopause and urinary incontinence for which he received the CDER Leadership Excellence Award. He later served as Director of the Division of Gastroenterology and Inborn Error Products from 2007 to 2008 where he received the FDA Outstanding Service Award for leadership.
What's Love Got to Do with It? Give Your Smartphone a Valentine's Gift This Year
PR Newswire - Wed Feb 12, 8:30AM CST
Whether planning a romantic night on the town with a sweetheart or a trip to the slopes to avoid Valentine's Day entirely, most tech users will admit they are in a serious relationship with their smartphone. Defend that love from all the bumps, dings and drops life throws at it with an OtterBox® protective case.
Bunge Purchases Corn Masa Flour Mill
PR Newswire - Fri Feb 07, 3:44PM CST
Bunge North America, the North American operating arm of Bunge Limited (NYSE: BG), announced that it has purchased the assets of Corn Flour Producers, LLC. Financial terms of the acquisition have not been released.
BG: 83.90 (+0.02)
SupersonicAds Announces Three Key Leadership Hires In North America
PR Newswire - Wed Jan 29, 7:17AM CST
SupersonicAds-- one of the world's leading web and mobile app monetization platforms--today announced an expansion of its North American leadership team with the creation of three new positions based at the company's headquarters.
Immunotech Laboratories, Inc. Announces the Results From Gap Analysis Report
GlobeNewswire - Wed Jun 19, 8:05AM CDT
Immunotech Laboratories, Inc. (Pink Sheets:IMMB) today announced the results from Gap Analysis report.
Immunotech Laboratories ITV-1 Manufacturing Announcement
GlobeNewswire - Thu May 30, 8:09AM CDT
Immunotech Laboratories, Inc. (Pink Sheets:IMMB) today announced the company has reached advanced negotiations for the production of Immunotech's ITV-1 Medicine with a reputed Contract manufacturing facility, for use in the Bulgarian Clinical Studies. All costs related to the production of the ITV-1 for this production will be facilitated by Immunotech's sister company in Bulgaria. (Immunotech BG).
Immunotech Laboratories Corporate Shareholder Update Summary
GlobeNewswire - Thu May 09, 8:00AM CDT
Immunotech Laboratories, Inc. (Pink Sheets:IMMB) Immunotech Laboratories, Inc. today released the following company updates for shareholders and Investors:
Immunotech Laboratories, Inc. Provides Funding Update
GlobeNewswire - Mon Apr 29, 10:11AM CDT
Immunotech Laboratories, Inc. (Pink Sheets:IMMB) today announced that they are in preliminary discussions with a large potential funding group out of Dubai. The group has shown interest in the future development and support of the Company's future FDA clinical trials.
Immunotech Laboratories Begins Regulatory Process With US Food & Drug Administration
Marketwire - Fri Apr 26, 8:00AM CDT
Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) today announced the company has initiated the Pre-IND and IND process with the US Food & Drug Administration (FDA). The successful submission of an Investigational New Drug (IND) to FDA will permit Immunotech to conduct clinical trials designed to result in marketing approval for a new drug.
Immunotech Laboraties Appoints New VP of Business Development
Marketwire - Mon Apr 15, 8:25AM CDT
Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) announces the company has appointed Blaine Nabors as VP of Business Development.